Resolution of the Expert Council “Open questions in the management of patients with neuronal ceroid lipofuscinosis type 2”

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

References

  1. Aylward S.C., Pindrik J., Abreu N.J. et al. Cerliponase alfa for CLN2 disease, a promising therapy. Expert Opin Orphan Drugs 2020;8(11):445–54.
  2. Boop S., Nistal D., Barrios-Anderson A. et al. Novel surgical approach for intraventricular cerliponase alfa enzyme replacement therapy via central venous access device (CVAD) port in neuronal ceroid lipofuscinosis type 2 (CLN2) disease. Childs Nerv Syst 2025;41(1):172. doi: 10.1007/s00381-025-06822-4
  3. Breuillard D., Ouss L., Le Normand M.T. et al. Ceroid lipofuscinosis type 2 disease: effective presymptomatic therapy – oldest case of a presymptomatic enzyme therapy. Eur J Neurol 2024;31(9):e16324. doi: 10.1111/ene.16324
  4. Brineura Treatment for CLN2 Disease – The Managed Access Agreement. Available at: https://www.rd-rp.com/managed-access-agreement-resources.
  5. Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, and the New York State Department of Health. “Conditions Screened”. GUARDIAN Study. 2021. Available at: https://guardian-study.org/overview/.
  6. De Los Reyes E., Lehwald L., Augustine E.F. et al. Intracerebroventricular cerliponase alfa for neuronal ceroid lipofuscinosis type 2 disease: clinical practice considerations from US clinics. Pediatr Neurol 2020;110:64–70. doi: 10.1016/j.pediatrneurol.2020.04.018
  7. EMA. Available at: https://www.ema.europa.eu/.
  8. FDA. Available at: https://www.fda.gov/.
  9. Fote G.M., Schafenacker A., Singh J. et al. Management of positive cerebrospinal fluid cultures from intraventricular reservoirs of neuronal ceroid lipofuscinosis type 2 patients: one institution’s experience. J Neurosurg Pediatr 2025;36(5):649–56. doi: 10.3171/2025.4.PEDS24452
  10. Jones S.A., Cheillan D., Chakrapani A. et al. Application of a novel algorithm for expanding newborn screening for inherited metabolic disorders across Europe. Int J Neonatal Screen 2022;8(1):20. doi: 10.3390/ijns8010020
  11. Kovacs K.D., Patel S., Orlin A. et al. Symmetric age association of retinal degeneration in patients with CLN2-associated Batten disease. Ophthalmol Retina 2020;4(7):728–36. doi: 10.1016/j.oret.2020.01.011
  12. Mole S.E., Schulz A., Badoe E. et al. Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. Orphanet J Rare Dis 2021;16(1):185. doi: 10.1186/s13023-021-01813-5
  13. Nickel M., Simonati A., Jacoby D. et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health 2018;2(8):582–90. doi: 10.1016/S2352-4642(18)30179-2
  14. Orlin A., Sondhi D., Witmer M.T. et al. Spectrum of ocular manifestations in CLN2-associated batten (Jansky–Bielschowsky) disease correlate with advancing age and deteriorating neurological function. PLoS One 2013;8(8):e73128. doi: 10.1371/journal.pone.0073128
  15. Priglinger C., Courage C., Maier E.M. et al. Enzyme replacement therapy in CLN2-associated retinopathy. Klin Monbl Augenheilkd 2025;242(3):213–8. doi: 10.1055/a-2528-7886
  16. Read J., Donald A., Rhead S. et al. Chest-sited intraventricular access devices for cerliponase alfa infusion in Batten disease at a single tertiary United Kingdom pediatric center. J Neurosurg Pediatr 2025;37(1):87–94. doi: 10.3171/2025.7.PEDS25222
  17. Rodrigues D., de Castro M.J., Crujeiras P. et al. The LINCE Project: a pathway for diagnosing NCL2 disease. Front Pediatr 2022;10:876688. doi: 10.3389/fped.2022.876688
  18. Rogers D.L., Blind J.E., Kienzle T. et al. Same-day approach for combined intravitreal and intracerebroventricular enzyme replacement therapy to prevent retinal disease progression in children with neuronal ceroid lipofuscinosis type 2. Pediatr Neurol 2025;170:1–3. doi: 10.1016/j.pediatrneurol.2025.06.007
  19. Sampaio L.P.B., Manreza M.L.G., Pessoa A. et al. Clinical management and diagnosis of CLN2 disease: consensus of the Brazilian experts group. Arq Neuropsiquiatr 2023;81(3):284–95. doi: 10.1055/s-0043-1761434
  20. Schulz A., de los Reyes E., Specchio N. et al. Cerliponase alfa for the treatment of CLN2 disease in a patient cohort including children under 3 years of age. 20th Annual World Symposium, 2024, San Diego, USA.
  21. Schulz A., Ajayi T., Specchio N. et al. CLN2 Study Group. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med 2018;378(20):1898–907. doi: 10.1056/NEJMoa1712649
  22. Schwering C., Kammler G., Wibbeler E. et al. Development of the “Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease” based on 6 years treatment experience in 48 patients. J Child Neurol 2021;36(8):635–41. doi: 10.1177/0883073821989154
  23. Shock M., Nigro E., Donner E.J., Whitney R. CLN2 disease: current understandings, challenges, and future directions. J Child Neurol 2026;41(1):118–34. doi: 10.1177/08830738251374539
  24. Specchio N., Pietrafusa N., Trivisano M. Changing times for CLN2 disease: the era of enzyme replacement therapy. Ther Clin Risk Manag 2020;16:213–22. doi: 10.2147/TCRM.S241048
  25. Warrier V., Vieira M., Mole S.E. Genetic basis and phenotypic correlations of the neuronal ceroid lipofusinoses. Biochim Biophys Acta 2013;1832(11):1827–30. doi: 10.1016/j.bbadis.2013.03.017
  26. Wawrzynski J., Martinez A.R., Thompson D.A. et al. First in man study of intravitreal tripeptidyl peptidase 1 for CLN2 retinopathy. Eye (Lond) 2024;38(6):1176–82. doi: 10.1038/s41433-023-02859-4
  27. Williams R.E., Adams H.R., Blohm M. et al. Management strategies for CLN2 disease. Pediatr Neurol 2017;69:102–12. doi: 10.1016/j.pediatrneurol.2017.01.034

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 ABV-Press

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-90927 от  13.02.2026.